Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $673.82
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 23, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 26, 26 | Weisler Dion J | director | A-Award | 56 | — |
| Citigroup |
| maintain |
| Buy |
| Buy |
| Oct 22, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Oct 22, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 22, 26 | Baird | maintain | Outperform | Outperform |
| Oct 22, 26 | Stifel | maintain | Buy | Buy |
| Oct 22, 26 | Barclays | maintain | Overweight | Overweight |
| Oct 13, 26 | TD Cowen | maintain | Buy | Buy |
| Oct 13, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Oct 7, 26 | Barclays | maintain | Overweight | Overweight |
| Sep 26, 26 |
| Sperling Scott M |
| director |
| A-Award |
| 63 |
| — |
| Sep 26, 26 | Lynch Karen S | director | A-Award | 46 | — |
| Sep 26, 26 | Keith R. Alexandra | director | A-Award | 46 | — |
| Sep 26, 26 | Johnson Jennifer M | director | A-Award | 46 | — |
| Aug 28, 26 | Casper Marc N | director, officer: Chairman & CEO | F-InKind | 725 @ $622.18 | $450.9K |
| Aug 28, 26 | Casper Marc N | director, officer: Chairman & CEO | F-InKind | 532 @ $622.18 | $330.9K |
| Aug 28, 26 | Meyer James | officer: Sr. Vice President & CFO | F-InKind | 37 @ $622.18 | $23.16K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some of the week's most closely watched names.
Thermo Fisher Scientific Inc. delivered strong Q3 results, with 6% organic growth, EPS and sales beats, and raised full-year guidance. TMO's growth is driven by robust demand in clinical research, bioproduction, and electron microscopy, supported by recent strategic acquisitions. Operating margin reached 24.5%, aided by divestitures, acquisitions, and ongoing process improvements.
Thermo Fisher raised its 2026 organic revenue growth outlook to 4%. Third-quarter revenue reached $12.14 billion with 6% organic growth.
Life-sciences tools giant Thermo Fisher Scientific (TMO) reported a strong third quarter Wednesday, with revenue up 9% and adjusted earnings per share up 15%. S
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 1% on Wednesday.
Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript
Thermo Fisher beats Q3 earnings and revenue estimates, with double-digit profit growth and wider margins, yet shares fall 4.1% in pre-market trading.
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Oct 21, 2026 | 6.40 | 6.68 | Beat 4.4% | $12.14B |
| Jul 23, 2026 | 5.72 | 6.03 | Beat 5.4% | $11.99B |
| Apr 23, 2026 | 5.25 | 5.44 | Beat 3.6% | $11.01B |
| Jan 29, 2026 | 6.45 | 6.57 | Beat 1.9% | $12.21B |
| Oct 22, 2025 | 5.50 | 5.79 | Beat 5.3% | $11.12B |
| Jul 23, 2025 | 5.23 | 5.36 | Beat 2.5% | $10.86B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 21, 2026 | 2026-10-21 06:03:16 | View |
| 4 | Sep 29, 2026 | 2026-09-29 16:14:05 | View |
| 4 | Sep 29, 2026 | 2026-09-29 16:13:58 | View |
| 4 | Sep 29, 2026 | 2026-09-29 16:13:50 | View |
| 4 | Sep 29, 2026 | 2026-09-29 16:13:42 | View |
| 4 | Sep 29, 2026 | 2026-09-29 16:13:34 | View |
| 4 | Sep 1, 2026 | 2026-09-01 16:11:16 | View |
| 4 | Sep 1, 2026 | 2026-09-01 16:11:10 | View |
| 4 | Sep 1, 2026 | 2026-09-01 16:11:04 | View |
| 4 | Sep 1, 2026 | 2026-09-01 16:10:59 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | TMO | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 35.5x | 32.6x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 26.7x | EPS est. 25.23 | Discount |
| Price / Book | 4.6x | 4.8x | In line |
| Price / Sales | 5.3x | 5.2x | In line |
| EV / EBITDA | 25.4x | 21.3x | Elevated |
| Return on equity | 13.3% | — | Healthy |
| Gross margin | 41.4% | 43.0% | In line |
| Debt / Equity | 0.76 | 0.78 | Moderate |
| Piotroski / Altman Z | 7/9 | Z 3.31 | Safe zone |
Discounted cash flow model
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 53.81 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 65.47 | Oscillator | Neutral |
| Williams %R (14) | -45.37 | Oscillator | Neutral |
| MACD (12, 26, 9) | 11.16 (Hist -1.21) | Oscillator | Sell |
| Average Directional Index (14) | 33.56 (+DI 20.5 / -DI 18.9) | Trend | Strong Buy |
| EMA 20 | 670.95 | MA | Buy |
| SMA 20 | 672.10 | MA | Buy |
| EMA 50 | 642.96 | MA | Strong Buy |
| SMA 50 | 644.96 | MA | Strong Buy |
| SMA 200 | 549.28 | MA | Strong Buy |